Largan Precision has successfully entered the medical field, with both Largan Health AI-TECH and Largan Medical entering the recovery period.
Largan Precision's CEO, Lin En-Ping, mentioned that after a decade of success in the medical field, the group's subsidiary, Largan Health AI-TECH, has started shipping the new generation sleep detection system this year. Additionally, the investment in Largan Medical also achieved a modest profit last year, marking medical equipment as the third pillar of Largan Precision's operations. Lin En-Ping stated that according to statistics, around 40-50% of people in Taiwan suffer from sleep disorders. Due to a positive outlook on significant market demand for sleep disorders in Taiwan, Largan Precision established Largan Health AI-TECH (LHT), holding a 40% stake with a capital of 3 billion NTD. The company primarily focuses on developing medical-grade electrocardiograms (ECG) for sleep detection. After years of research and development, Largan Health AI-TECH will promote a new generation sleep detection system. Although this product is not closely related to optical technology, Largan Precision is responsible for the main chip design and product assembly.
As a holding company, Largan Health AI-TECH includes a research team in the USA, an internal production and research unit within Largan Precision, and a subsidiary in China called Fengsheng, responsible for marketing in China. Lin En-Ping indicated that the company has obtained FDA ,CFDA ,and TFDA certificate. The product is expected to start shipping this year, contributing the revenues to Largan Precision's performance. Lin En-Ping explicitly stated that Largan Health AI-TECH has entered the recovery period starting this year.
Regarding the indirect investment in Largan Medical through its subsidiary, Deyang Technology, with a holding of approximately 40.5%, Lin En-Ping mentioned that Largan Medical entered the Chinese market in the middle of last year and expanded into overseas markets such as Hong Kong and Macau. With distribution channels reaching 2,000 points in Taiwan and being available in 400 Watsons stores, Largan Medical turned losses into profits in the second half of last year, achieving a break-even or even a small profit for the whole year. It is expected to further contribute to Largan Precision's expansion this year.